HealthRX.com · Printable side-effect diary
Wegovy vomiting week-by-week diary
One line for each week of treatment: the dose, how many days you vomited and whether you kept fluids down, so you can see whether vomiting is following a dose step or lasting beyond it. Bring it to any call about delaying the next increase or about a missed injection.
Treatment start
Date of the first Wegovy injection
Injection day of the week
Current dose, and the week it started
Weekly record
Week 1 is the week of your first injection.
| Week of treatment | Dose that week | Days with vomiting | Most episodes in one day | Fluids kept down every day? | Remedy or antiemetic used | Next step held or delayed? |
|---|---|---|---|---|---|---|
What the label and the pooled trials show
- The label's injection schedule starts at 0.25 mg in weeks 1 to 4 and reaches the maintenance dose from week 17.[1]
- If a dose is not tolerated during escalation, the label says to consider delaying the next step for 4 weeks.[1]
- Missed injection: if the next dose is more than 2 days away, inject as soon as possible; if it is less than 2 days away, skip the missed dose.[1]
- After 2 or more missed doses in a row, the label says to restart escalation at a lower dose.[1]
- In pooled STEP 1 to 3, vomiting was most common at about week 20, and one episode lasted a median of 2 days.[2]
Call now instead of waiting for the next step
- Severe pain in your stomach area that will not go away, with or without vomiting: stop Wegovy and call your healthcare provider right away.[1]
- Vomiting that does not go away: tell your healthcare provider right away; losing fluids can lead to kidney problems.[1]
For the call about the next dose
- Does my vomiting match the last dose step, or has it gone on beyond it?
- Should the next increase wait, and for how long?
- Is an antiemetic right for me, given my other medicines?
- What should I do with an injection that falls due during a vomiting spell?
Sources for the facts on this sheet
- Novo Nordisk, via DailyMed. Wegovy (semaglutide) injection and tablets: prescribing information and Medication Guide. Effective 2026-06-18. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022. PMID 34514682. https://pubmed.ncbi.nlm.nih.gov/34514682/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.